Par/Advancis Pulsatile Amoxicillin Filing Plans On Hold After Phase III Failure
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A potential NDA submission for Advancis' Pulsys pulsatile amoxicillin formulation will be delayed at least until late 2006 following failure of a Phase III trial to show statistical non-inferiority to penicillin
You may also be interested in...
Advancis’ Last Try For Pulsys Platform? New Phase III Trial To Start In November
Advancis is prepared to begin a new Phase III trial of its Pulsys pulsatile amoxicillin formulation in November in hopes of following through with its previously planned NDA
Amoxicillin Pulsys NDA plans
Advancis anticipates a second-half 2005 NDA filing for its amoxicillin Pulsys formulation, using the firm's once-a-day pulsatile delivery technology. A Phase III trial in adolescents and adults with acute pharyngitis and/or tonsillitis due to Group A streptococcal infections began dosing Oct. 15, with results expected in the first half of 2005. GlaxoSmithKline terminated development of an Augmentin Pulsys formulation, effective Dec. 15. "Advancis remains confident that pulsatile amoxicillin/clavulanate is technically and commercially viable, and will be exploring other avenues and partners. Additionally, the company believes continued progress on its pulsatile version of amoxicillin will help support future productive Pulsys collaborations," Advancis says...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011